Engflag

Cuvposa Solution

Quick links to important sections

Cuvposa Solution

There is no image.

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cuvposa Solution

Quick Facts: Cuvposa Solution

Property Description
Active ingredient Glycopyrrolate (Glycopyrronium bromide)
Form Oral Solution (Liquid formulation)
Pharmacological Class Anticholinergic Agent
Origin Synthetic compound (Quaternary ammonium)
General Purpose Reduction of excessive glandular secretions

What Type of Medicine is Cuvposa Solution?

Cuvposa Solution is a specialized, prescription medicine formulated as a single-ingredient product. Its active component is Glycopyrrolate, also formally recognized as Glycopyronium bromide. This drug is classified as an anticholinergic agent, specifically identified as an antimuscarinic agent. Glycopyrrolate is a synthetic compound, manufactured to achieve a precise and reliable physiological action by modulating nerve signals. This specific pharmacological class is clinically recognized for its effect on glandular output, which is the core principle of its function.

Composition and Dosage Form

The preparation is provided as an Oral Solution, a ready-to-use liquid formulation designed for systemic administration by mouth. The active component, Glycopyrrolate, features a quaternary ammonium compound structure, which is designed to limit the drug's activity primarily to the body's peripheral systems, focusing its action on the glands. This specific liquid formulation in an aqueous vehicle is key, as its design facilitates the accurate and fine-tuned dosing necessary for its target audience, primarily pediatric patients 3 years of age and older.

General Therapeutic Purpose

The overall function of this anticholinergic agent is the reduction of glandular secretions by inhibiting the signals that cause excessive fluid release. The general therapeutic purpose of the Cuvposa Oral Solution is to manage conditions associated with the unwanted overproduction of fluids. This medication is intended to provide systemic relief for patients suffering from chronic severe drooling (sialorrhea), offering a means to control the hypersecretion and improve comfort. This pharmacological action enables the solution to target and inhibit the processes that stimulate saliva and other exocrine gland output.

Regulatory References

  1. NIH MedlinePlus Glycopyrrolate Drug Information

What side effects are possible with Cuvposa Solution?

Possible Side Effects and Safety Information

Cuvposa Solution (glycopyrrolate) carries documented safety information primarily related to its anticholinergic properties. These effects stem from the medicine reducing the action of acetylcholine, which impacts various systems in the body.

Common and Serious Adverse Reactions

The most frequently reported adverse reactions (occurring in 30% or more of patients) include dry mouth, vomiting, constipation, flushing, and nasal congestion. Other commonly reported reactions (incidence ge15%) are headache, sinusitis, upper respiratory tract infection, and urinary retention.

Serious adverse reactions may include constipation or intestinal pseudo-obstruction (a non-mechanical blockage of the intestines) and incomplete mechanical intestinal obstruction, the latter of which may sometimes present as diarrhea. Close monitoring for signs of constipation or obstruction is particularly important within 4–5 days of starting the medication or following a dose increase.

Safety Warnings and Contraindications

Heat prostration (fever and heat stroke due to decreased sweating) is a documented risk, and exposure to high ambient temperatures should be avoided. The medication may also cause drowsiness or blurred vision, and caution is advised for activities requiring mental alertness, such as operating a vehicle or machinery.

Cuvposa is contraindicated in patients with medical conditions that prohibit anticholinergic therapy, including glaucoma, paralytic ileus, toxic megacolon complicating ulcerative colitis, severe ulcerative colitis, myasthenia gravis, or unstable cardiovascular status in acute hemorrhage. The solution is also contraindicated for use in patients taking solid oral dosage forms of potassium chloride.

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose of Glycopyrrolate Solution is described in regulatory documents as an exaggeration of anticholinergic effects, which are primarily peripheral in nature. Documented clinical manifestations include blurred vision, confusion, dizziness or lightheadedness upon standing, muscle weakness, and altered heat regulation that may increase the risk of heat prostration. Cardiovascular effects such as severe tachycardia and cardiac arrhythmias are also documented.

Certain clinical presentations are designated as severe indicators requiring immediate action. These include collapse, seizure, and the inability to be awakened (unconsciousness). Official guidance mandates specific emergency actions for these life-threatening signs. You must seek immediate medical attention and call emergency services (911) if the affected person has collapsed, is seizing, or has trouble breathing. Additionally, you are instructed to call the poison control helpline.

Treatment for overexposure is defined as supportive in nature because no specific antidote is known to the poisoning. Management procedures documented in regulatory materials emphasize maintaining vital functions and include fever control, administration of oxygen, and fluid replacement as necessary.

Therapeutic Uses of Cuvposa Solution

What Cuvposa Solution Treats: Main Uses and Benefits

Cuvposa Solution is a specialized prescription medication commonly used to help with symptoms that create noticeable physiological strain. Its primary indication is relevant for easing and supporting the management of chronic severe drooling (sialorrhea) in pediatric patients.

Symptom Management and Therapeutic Focus

The medication is generally used for managing symptom clusters that may become intense or disruptive, specifically targeting symptoms that create noticeable functional strain. This is primarily applied in clinical scenarios involving underlying neurological conditions, such as Cerebral Palsy, where symptoms that interfere with daily functioning are persistent. The listing of indications centers on the symptomatic support for chronic conditions where functional stability becomes affected.

The medication supports the management of symptoms that interfere with daily comfort. It is relevant for easing distress and contributes to improved day-to-day comfort, which may help patients cope more steadily with symptom fluctuations. By easing the overall symptom load, the solution may assist with maintaining functional stability and supports general well-being during symptomatic phases for the patient and their caregivers.

Quick Fact Block

Quick Fact: Symptomatic Support for Chronic Severe Drooling
Symptom Category Symptoms related to systemic imbalance
Condition Type Conditions presenting with systemic or localized discomfort (e.g., Sialorrhea)
Typical Context Applied in scenarios where additional management of discomfort is required in children with neurological conditions
Primary Benefit Provides support that helps ease the overall symptom burden and assists with maintaining functional stability

Eligibility and Restrictions for Use

Cuvposa (glycopyrrolate) oral solution is indicated for pediatric patients aged 3 to 16 years to reduce chronic, severe drooling associated with neurological conditions, such as cerebral palsy. Its use outside this age range is not established.

Contraindications (Who Should Not Use Cuvposa?)

Cuvposa is an anticholinergic medication and is contraindicated for use in patients with medical conditions that could be worsened by this class of drugs. It should not be given to individuals with:

  • Glaucoma (specifically angle-closure glaucoma).
  • Severe gastrointestinal (GI) conditions such as paralytic ileus, toxic megacolon complicating severe ulcerative colitis, or loss of normal bowel tone.
  • Myasthenia gravis, a neuromuscular disease.
  • Unstable cardiovascular status in the presence of acute hemorrhage.
  • Difficulty urinating due to conditions like bladder-neck obstruction or prostatic hypertrophy.
  • Concurrent use of solid oral dosage forms of potassium chloride, which can lead to GI lesions due to delayed passage.

Precautions (Use with Caution)

Healthcare providers must exercise caution when prescribing Cuvposa to patients with other conditions, including certain heart problems (coronary artery disease, high blood pressure, or rapid heart rhythm), kidney problems, ulcerative colitis, hyperthyroidism, or hiatal hernia with reflux esophagitis.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction scope

Category Official Regulatory Information
Medicinal product categories with documented interactions: Anticholinergic agents; Tricyclic antidepressants; Antihistamines; Phenothiazines; Anticholinesterases; Botulinum Toxin; Solid oral forms of potassium chloride.
Specific interacting medicines (if explicitly listed): Solid oral dosage forms of Potassium chloride; Digoxin tablets; Atenolol; Metformin; Haloperidol; Levodopa.
Mechanistic basis of interactions (only if stated in label): Pharmacodynamic Reinforcement (additive anticholinergic effects); Drug-induced reduction of gastrointestinal motility (alters absorption and contact time of co-administered drugs); Pharmacokinetic alteration by food (reduced absorption and systemic exposure).
Timing-based interaction rules (if applicable): The product must be administered at least one hour before or at least two hours after meals to avoid a significant reduction in systemic exposure.
Population-specific interaction notes (if applicable): Elderly patients may be more susceptible to the additive anticholinergic effects, including confusion.
Interaction-related restrictions: Co-administration is contraindicated with solid oral dosage forms of Potassium chloride. Co-administration with other anticholinergic medicines may be contraindicated due to the potential for severe additive effects.

Interaction classifications (high-level)

Classification Official Regulatory Information
Interaction severity classification (as defined in official documents): Contraindicated Combination (with solid oral potassium chloride); Clinically Significant Risk (with other anticholinergics due to additive effects).
Regulatory basis (EMA / FDA / etc.): Primarily based on FDA-approved Prescribing Information and EMA Summary of Product Characteristics.
Interaction-context constraints (as defined in official documents): Administration must be separated from food to maintain systemic exposure. Co-administration of solid oral potassium chloride is prohibited due to risk of local tissue injury.

Resulting interaction structure

Official interaction statements:

  • The co-administration of solid oral dosage forms of potassium chloride is formally contraindicated due to the risk of severe gastrointestinal lesions caused by the drug's effect of reduced gastrointestinal motility.
  • Co-administration with other anticholinergic agents (e.g., tricyclic antidepressants, antihistamines) may lead to additive pharmacodynamic effects, which increase the risk and severity of anticholinergic-related adverse reactions.
  • The medicine may increase serum levels of co-administered digoxin tablets, atenolol, or metformin, and may decrease serum levels of haloperidol or levodopa.
  • The absorption and systemic exposure of the medicine are significantly reduced when administered with a high-fat meal.

Connection to the overall interaction profile:

The regulatory documents define the product's interaction structure primarily through two domains: pharmacodynamic reinforcement with other anticholinergic agents, leading to additive systemic effects, and drug-induced change in gastrointestinal motility, which creates both a specific severe interaction constraint and affects the absorption of co-administered drugs. Furthermore, the label stipulates a mandatory timing-based rule to manage the significant pharmacokinetic interaction with food, which reduces systemic exposure.

Mechanism of Action

How Cuvposa Solution Works

Cuvposa (glycopyrrolate) exerts its pharmacodynamic effect through a targeted anticholinergic mechanism, primarily modulating the activity of the parasympathetic nervous system. It functions as a highly specific, competitive inhibitor that acts upon muscarinic acetylcholine receptors (mAChRs) located on the effector cells of peripheral exocrine glands.

By binding to these receptors, glycopyrrolate blocks the action of the endogenous neurotransmitter, acetylcholine. This antagonistic interaction prevents the initiation of the cholinergic signaling cascade within the glandular cells. The molecular consequence of this receptor blockade is the suppression of the normal secretory pathway. This results in the direct modulation of glandular secretion volume at the system level, influencing physiological processes dependent on acetylcholine-mediated exocrine activity.

Dosage and Administration Information

How to Use Cuvposa Solution

Cuvposa (glycopyrrolate) is an oral solution administered by mouth, specifically indicated for use in pediatric patients aged 3 to 16 years who experience chronic severe drooling (sialorrhea). The usage protocol emphasizes a structured, gradual dosing schedule to establish the required therapeutic level.

Official Administration Protocol

The solution is designed to be measured and administered using a calibrated oral device, such as an accurate syringe or measuring cup, to ensure the correct volume of the 1 mg/5 mL solution is given. Dosing is based on the child's body weight (mg/kg) and is administered three times daily (TID).

Dosing Initiation and Titration

Treatment begins with a low initial dose of 0.02 mg/kg per dose. The use protocol requires an initial titration period, typically lasting four weeks, during which the dose is adjusted incrementally. The dose may be increased by 0.02 mg/kg every 5 to 7 days, allowing for a gradual adjustment until the optimal dose is identified. The maximum recommended dose is 0.1 mg/kg per dose, not to exceed 3 mg per dose, regardless of weight calculation.

Contextual Usage Instructions

A critical component of the administration process is the timing in relation to food. Cuvposa Solution must be administered at least one hour before or two hours after meals to ensure consistent absorption, as food intake can significantly reduce the medicine's bioavailability. If a dose is missed, the standard procedure is to skip the missed dose and resume the normal schedule at the next designated time, without attempting to double the dose.

Recent Clinical Evidence

Research evidence / Overview of studies for Cuvposa Solution

1. Evidence for the Management of Chronic Severe Drooling (Sialorrhea)

Research on chronic severe drooling was evaluated in structured, short-term Randomized, Double-blind, Placebo-controlled Trials (RCTs). These studies explored the medicine's effects in pediatric patients (children aged 3 to 16 years) experiencing drooling linked to underlying neurologic conditions. Researchers monitored changes in drooling severity using a subjective measure, the modified Teacher’s Drooling Scale (mTDS). Findings describe patterns observed in the studies over the short eight-week period.

2. Research on Long-Term Outcomes and Follow-up

To obtain data beyond controlled trials, Open-label Extension Studies observed responses for up to 24 weeks. These studies contribute to contextualizing patient experience but lack the rigorous design of the primary RCTs. Long-term effects are not fully established for this chronic condition, and data on durability over many years are still emerging.

3. Evidence in Specific Patient Populations

The evidence base specifically focuses on the pediatric population (3 to 16 years) with drooling linked to neurologic conditions. Since results apply only to the populations studied, limited information exists for other patient groups, such as older adults or infants. Findings describe group patterns, not personal outcomes.

4. Quality and Context of the Evidence

Clinical assessments note that the overall evidence quality in the primary research is based on the type of studies conducted. The synthesis relies on a single pivotal trial conducted using a high-quality, controlled design. Outcomes were measured using a subjective patient-reported outcomes scale, meaning that certainty remains low regarding the exact clinical importance of the reported findings.

5. What Remains Uncertain About Cuvposa Solution Research

Several areas remain uncertain. The main controlled trial had a modest sample size, meaning the results apply only to the specific conditions studied. Comparative evidence is lacking to assess the solution against other active treatments, as initial trials primarily used a placebo comparison. These factors contribute to the ongoing uncertainty about the medicine's profile in routine clinical settings.

Key Studies & References Clinical Review Report: Glycopyrrolate Oral Solution (Cuvposa) - NCBI Bookshelf (Systematic Review/Assessment)

Frequently Asked Questions (FAQ)

Common questions about Cuvposa Solution (FAQ)

Q: How quickly does Cuvposa Solution start working?

A: Studies and official information indicate that some patients treated with Cuvposa began to see a reduction in drooling as early as four weeks into treatment. The primary assessment of the medicine's effectiveness was conducted at the end of the eight-week clinical study.

Q: How long does the effect of Cuvposa Solution last?

A: The official product information indicates that Cuvposa is prescribed to be taken three times daily (TID). This dosing schedule is the recommended frequency for administration to help manage the condition.

Q: Can Cuvposa Solution be mixed with food or drink?

A: Regulatory documents state that the solution must be taken at least one hour before or two hours after meals. This is because taking it with food significantly reduces how much medicine the body absorbs. The official label does not provide specific instructions for mixing with non-meal liquids like plain water. Questions about administration outside of the official label should be directed to a healthcare provider.

Q: Is Cuvposa Solution the same as generic glycopyrrolate?

A: Cuvposa contains the active ingredient glycopyrrolate. However, the specific oral solution formulation was reviewed by the FDA, which determined that it is not bioequivalent to previously approved glycopyrrolate tablets. This means the way the body handles the liquid solution is different from the tablet form.

Q: Does Cuvposa Solution stop all drooling completely?

A: Studies and official information indicate that Cuvposa is prescribed to reduce chronic severe drooling, not necessarily eliminate it. Clinical trials measured the reduction in drooling severity, and in the pivotal study, 75% of patients had less drooling after eight weeks than before treatment.

Q: Is it normal to feel a bit dizzy after taking Cuvposa Solution?

A: Regulatory documents mention that Cuvposa may cause drowsiness or blurred vision as potential side effects. Official sources also suggest that dizziness can occur with the use of oral glycopyrrolate.

Q: Is Cuvposa Solution safe to use long-term?

A: Safety and effectiveness information is primarily based on an initial eight-week, placebo-controlled trial and a follow-up 24-week safety study. Regulatory documents state that the long-term effects of use beyond six months are not yet fully established according to the clinical studies.

Q: Can I use Cuvposa Solution if I have kidney problems?

A: Regulatory documents state that caution is needed when Cuvposa is used in patients with renal impairment (kidney problems). This is because the medicine is primarily removed from the body by the kidneys.

Q: Does Cuvposa Solution interact with allergy or cold medications?

A: Official information states that Cuvposa can have additive anticholinergic effects when combined with other anticholinergic drugs, such as antihistamines which are often found in allergy and cold medications. This combination may increase the risk of side effects like dry mouth and constipation.

Q: Does alcohol affect Cuvposa Solution?

A: Regulatory documents indicate that caution is advised with the combination of Cuvposa and alcohol, as it may cause or worsen side effects such as drowsiness and blurred vision.

Q: What happens if Cuvposa Solution is taken with certain liquid foods?

A: Cuvposa must be given at least one hour before or two hours after meals to ensure consistent absorption. Taking it with any food—including liquid food or high-fat meals—can significantly reduce the amount of medicine the body receives, reducing its effectiveness.

Q: Where can I find the official prescribing information for Cuvposa Solution?

A: The official prescribing information can be found on the FDA website or in the DailyMed database, which contain the most current regulatory labeling for the product.

Q: What is the 'active ingredient' and 'inactive ingredients' in Cuvposa Solution?

A: The active ingredient in the solution is glycopyrrolate. Official product labeling lists the inactive ingredients as citric acid, glycerin, natural and artificial cherry flavor, methylparaben, propylene glycol, propylparaben, saccharin sodium, sodium citrate, sorbitol solution, and purified water.

Q: Can Cuvposa Solution affect my heart rate?

A: Regulatory warnings state that Cuvposa should be used with caution in people who have heart conditions such as rapid heart rhythm (tachycardia) or coronary artery disease. As an anticholinergic drug, it has the potential to affect the heart rate.

Q: Is it possible to have an allergic reaction to Cuvposa Solution?

A: Yes, official information states that glycopyrrolate is contraindicated for patients with a known hypersensitivity (allergic reaction) to the drug or its ingredients. Symptoms of a serious allergic reaction may include difficulty breathing, swelling, or hives.

Q: Does Cuvposa Solution contain sugar or gluten?

A: The official list of inactive ingredients includes saccharin sodium (a sugar substitute) and sorbitol solution (a sugar alcohol). The regulatory label does not list gluten as an ingredient.

Q: Is Cuvposa Solution a controlled substance?

A: Official regulatory classification indicates that Cuvposa (glycopyrrolate) is a prescription medicine but is not classified as a controlled substance under the DEA schedules.

Q: Does Cuvposa Solution interact with antacids or medicines for stomach issues?

A: Official documents state that Cuvposa reduces how quickly the contents of the stomach and intestines move, which can affect the absorption of other medicines. It is also used with caution in patients who have certain stomach issues, such as hiatal hernia and reflux esophagitis.

Q: Does Cuvposa Solution have a 'Black Box Warning'?

A: No, the FDA-approved labeling for Cuvposa oral solution does not contain a Boxed Warning, which is commonly referred to as a 'Black Box Warning'.

Q: What does the term 'chronic severe drooling' mean in relation to Cuvposa Solution?

A: In the clinical studies supporting the drug’s use, 'problem drooling' was often defined as drooling severe enough that clothing became damp on most days of the week (approximately five to seven days per week). Severity was measured using the Modified Teacher's Drooling Scale (mTDS).

How should Cuvposa Solution be stored and disposed of?

Storage and Disposal of Cuvposa Solution

Cuvposa (glycopyrrolate) oral solution must be stored and handled according to specific regulatory requirements to maintain its stability and ensure safety.

Official Storage Conditions

The medicine must be kept in the original container and maintained at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The container must be kept tightly closed and stored away from excess heat and moisture.

Child-Safety and Disposal

For safety, the solution must be stored out of the sight and reach of children, and the safety cap must be locked. Patients are instructed to dispose of any unused or expired product by following local regulations. The medicine should remain in its tightly closed container until it is discarded.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Cuvposa Solution found in:

A-Z Index: